HORMAD1 and breast carcinoma: For example, in breast cancer, the CTAs CXorf61, HORMAD1, ACTL8 and PRAME are specifically enriched in basal subtypes, while the expression of PLAC1 and POTEC is more frequently observed in non-basal subtypes.15